Sinovac Biotech ROA 2024

Sinovac Biotech Aktienanalyse

What does Sinovac Biotech do?

Sinovac Biotech Ltd is a Chinese biopharmaceutical company specializing in researching, developing, manufacturing, and marketing vaccines for infectious diseases. The company was founded in 2001 and is headquartered in Beijing. The history of Sinovac began with the establishment of the company by CEO Dr. Yin Weidong. Dr. Yin was an experienced researcher in the field of vaccine development and had previously worked at the China Academy of Medical Sciences. His vision was to establish a company that produces innovative vaccines against severe and potentially life-threatening diseases. Sinovac's business model is based on the discovery and development of vaccines against viral diseases. The company works closely with leading research and development institutes in China to develop its products. It has several production facilities in China that meet the highest international standards and ensure excellent quality assurance. Sinovac specializes in various areas, including influenza, hepatitis, pneumococcal, rotavirus, rubella, and SARS vaccines. It is the only company in China authorized to manufacture and sell the inactivated seasonal flu vaccine used in China every year. Furthermore, Sinovac has successfully developed an inactivated hepatitis A vaccine and an inactivated Sinovac RS vaccine, which uses a unique technology to protect the vaccine against rejection reactions and adverse side effects. One of Sinovac's most significant products is the Sinovac CoronaVac vaccine, which is being used worldwide under emergency authorization by the World Health Organization to combat the Covid-19 pandemic. The vaccine has been successfully deployed in many countries worldwide and has shown high effectiveness against the virus. Sinovac also has a long history of collaborating with international organizations and governments to provide vaccines for the prevention of infectious diseases. It is an important supplier of vaccines to the Chinese government and has successfully developed vaccines against the swine flu epidemic and enterovirus, which are widespread in China. Overall, Sinovac is strongly committed to research, development, and manufacturing innovation. The company has taken a leadership role in combating infectious diseases in China and globally, and has an impressive track record in the development and production of vaccines at the highest level. Sinovac Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Sinovac Biotech's Return on Assets (ROA)

Sinovac Biotech's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Sinovac Biotech's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Sinovac Biotech's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Sinovac Biotech’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Sinovac Biotech Stock

What is the Return on Assets (ROA) of Sinovac Biotech this year?

The Return on Assets (ROA) of Sinovac Biotech is -0.01 undefined this year.

What was the ROA of Sinovac Biotech compared to the previous year?

The ROA of Sinovac Biotech has increased by -201.34% compared to the previous year.

What consequences do high ROA have for investors of Sinovac Biotech?

A high ROA is advantageous for investors of Sinovac Biotech, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Sinovac Biotech?

A low ROA can be unfavorable for investors of Sinovac Biotech as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Sinovac Biotech affect the company?

An increase in ROA of Sinovac Biotech can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Sinovac Biotech impact the company?

A reduction in the ROA of Sinovac Biotech can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Sinovac Biotech?

Some factors that can influence the ROA of Sinovac Biotech include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Sinovac Biotech important for investors?

The ROA of Sinovac Biotech is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Sinovac Biotech take to improve ROA?

To improve ROA, Sinovac Biotech can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Sinovac Biotech pay?

Over the past 12 months, Sinovac Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sinovac Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Sinovac Biotech?

The current dividend yield of Sinovac Biotech is .

When does Sinovac Biotech pay dividends?

Sinovac Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sinovac Biotech?

Sinovac Biotech paid dividends every year for the past 0 years.

What is the dividend of Sinovac Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sinovac Biotech located?

Sinovac Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinovac Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinovac Biotech from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Sinovac Biotech pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Sinovac Biotech in the year 2023?

In the year 2023, Sinovac Biotech distributed 0 USD as dividends.

In which currency does Sinovac Biotech pay out the dividend?

The dividends of Sinovac Biotech are distributed in USD.